{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:37:40Z","timestamp":1786991860273,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.jconrel.2014.11.004","type":"journal-article","created":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T03:18:17Z","timestamp":1415589497000},"page":"105-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides"],"prefix":"10.1016","volume":"197","author":[{"given":"Noriyasu","family":"Kamei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Takeda-Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2014.11.004_bb0005","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/bc800148t","article-title":"Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses","volume":"19","author":"Pardridge","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.addr.2011.11.014","article-title":"Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents","volume":"64","author":"Biddlestone-Thorpe","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0015","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood\u2013brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11095-010-0291-7","article-title":"In vivo methods to study uptake of nanoparticles into the brain","volume":"28","author":"van Rooy","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0025","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1083\/jcb.200302070","article-title":"Size-selective loosening of the blood\u2013brain barrier in claudin-5-deficient mice","volume":"161","author":"Nitta","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0030","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.bbamem.2008.09.016","article-title":"Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery","volume":"1788","author":"Deli","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1602\/neurorx.2.1.73","article-title":"Active efflux across the blood\u2013brain barrier: role of the solute carrier family","volume":"2","author":"Kusuhara","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejps.2008.06.015","article-title":"Pharmacokinetic role of l-type amino acid transporters LAT1 and LAT2","volume":"35","author":"del Amo","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0045","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1021\/jm8015409","article-title":"Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats","volume":"52","author":"Gynther","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0050","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)35388-1","article-title":"Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood\u2013brain barrier in mouse","volume":"292","author":"Lee","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0055","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/bit.21369","article-title":"Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood\u2013brain barrier","volume":"97","author":"Boado","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/bit.21764","article-title":"GDNF fusion protein for targeted-drug delivery across the human blood\u2013brain barrier","volume":"100","author":"Boado","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0065","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/jpet.109.165092","article-title":"Drug targeting of erythropoietin across the primate blood\u2013brain barrier with an IgG molecular Trojan horse","volume":"333","author":"Boado","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0070","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0075","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0080","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-1 to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0085","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","article-title":"Delivery of interferon-\u03b2 to the monkey nervous system following intranasal administration","volume":"152","author":"Thorne","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.103.063222","article-title":"Brain uptake of the glucagon-like-peptide-1 antagonist exendin (9\u201339) after intranasal administration","volume":"309","author":"Banks","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0095","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neulet.2008.10.090","article-title":"Direct transport of VEGF from the nasal cavity to brain","volume":"449","author":"Yang","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0100","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/brain\/awn288","article-title":"Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy","volume":"131","author":"Francis","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5381.2009.00057.x","article-title":"Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics","volume":"157","author":"Heitz","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0110","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.addr.2009.06.001","article-title":"Recent advances in the use of cell-penetrating peptides for medical and biological applications","volume":"61","author":"Fonseca","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jps.21117","article-title":"On the biomedical promise of cell penetrating peptides: limits versus prospects","volume":"97","author":"Foerg","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2008.08.001","article-title":"Usefulness of cell-penetrating peptides to improve intestinal insulin absorption","volume":"132","author":"Kamei","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2009.02.015","article-title":"Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide\/protein absorption using cell-penetrating peptides","volume":"136","author":"Kamei","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jconrel.2010.05.004","article-title":"Molecular imaging analysis of intestinal insulin absorption boosted by cell-penetrating peptides by using positron emission tomography","volume":"146","author":"Kamei","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jps.23364","article-title":"Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self-organizing maps","volume":"102","author":"Kamei","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2009.07.022","article-title":"Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins","volume":"381","author":"Khafagy","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2008.09.076","article-title":"Effect of cell-penetrating peptides on the nasal absorption of insulin","volume":"133","author":"Khafagy","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0290","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2014.06.022","article-title":"In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin","volume":"189","author":"Nielsen","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0155","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ejpb.2013.09.014","article-title":"One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats","volume":"85","author":"Khafagy","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12035-011-8229-6","article-title":"Brain insulin signaling and Alzheimer's disease: current evidence and future directions","volume":"46","author":"Schioth","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.npp.1301193","article-title":"Intranasal insulin improves memory in humans: superiority of insulin aspart","volume":"32","author":"Benedict","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0170","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.2042-7158.2012.01555.x","article-title":"Intranasal delivery of insulin via the olfactory nerve pathway","volume":"64","author":"Renner","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0175","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"Johnson","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0180","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1126\/science.285.5433.1569","article-title":"In vivo protein transduction: delivery of a biologically active protein into the mouse","volume":"285","author":"Schwarze","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0185","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1074\/jbc.272.25.16010","article-title":"A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus","volume":"272","author":"Vives","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0190","doi-asserted-by":"crossref","first-page":"10444","DOI":"10.1016\/S0021-9258(17)34080-2","article-title":"The third helix of the Antennapedia homeodomain translocates through biological membranes","volume":"269","author":"Derossi","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0195","doi-asserted-by":"crossref","first-page":"18188","DOI":"10.1074\/jbc.271.30.18188","article-title":"Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent","volume":"271","author":"Derossi","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0200","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1034\/j.1399-3011.2000.00723.x","article-title":"Polyarginine enters cells more efficiently than other polycationic homopolymers","volume":"56","author":"Mitchell","year":"2000","journal-title":"J. Pept. Res."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0205","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.addr.2007.10.006","article-title":"Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides","volume":"60","author":"Nakase","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0210","doi-asserted-by":"crossref","first-page":"15300","DOI":"10.1074\/jbc.M401604200","article-title":"Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors","volume":"280","author":"Richard","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0215","doi-asserted-by":"crossref","first-page":"34141","DOI":"10.1074\/jbc.M303045200","article-title":"Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins","volume":"278","author":"Fittipaldi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0220","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nm996","article-title":"Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis","volume":"10","author":"Wadia","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0225","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ymthe.2004.08.010","article-title":"Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement","volume":"10","author":"Nakase","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0230","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2004.10.018","article-title":"Cationic TAT peptide transduction domain enters cells by macropinocytosis","volume":"102","author":"Kaplan","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0235","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1600-0854.2007.00572.x","article-title":"A comprehensive model for the cellular uptake of cationic cell-penetrating peptides","volume":"8","author":"Duchardt","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0240","doi-asserted-by":"crossref","first-page":"33957","DOI":"10.1074\/jbc.M109.056309","article-title":"Translocation and endocytosis for cell-penetrating peptide internalization","volume":"284","author":"Jiao","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0245","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1074\/jbc.M805550200","article-title":"Cell entry of arginine-rich peptides is independent of endocytosis","volume":"284","author":"Ter-Avetisyan","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0250","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1002\/jps.23708","article-title":"Mechanistic study of the uptake\/permeation of cell-penetrating peptides across a Caco-2 monolayer and their stimulatory effect on epithelial insulin transport","volume":"102","author":"Kamei","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0255","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","article-title":"Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic","volume":"61","author":"Maher","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0260","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/187152710793361595","article-title":"Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders","volume":"9","author":"White","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0265","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","article-title":"GDNF, NGF and BDNF as therapeutic options for neurodegeneration","volume":"138","author":"Allen","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000346052","article-title":"Ghrelin as a GH-releasing factor","volume":"25","author":"Carreira","year":"2013","journal-title":"Endocr. Dev."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0275","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/272827a0","article-title":"Insulin receptors are widely distributed in the central nervous system of the rat","volume":"272","author":"Havrankova","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2014.11.004_bb0280","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1523\/JNEUROSCI.2860-04.2004","article-title":"Insulin-degrading enzyme as downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention","volume":"24","author":"Zhao","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2014.11.004_bb0285","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1212\/01.wnl.0000324925.95210.6d","article-title":"Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology","volume":"71","author":"Beeri","year":"2008","journal-title":"Neurology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591400741X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591400741X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T12:18:21Z","timestamp":1747138701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591400741X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":57,"alternative-id":["S016836591400741X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.11.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}